SCHEMBL6519610

SCHEMBL6519610

CC(=O)c1c(O)c2cc(F)ccc2[nH]c1=O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 1/20 0.56
KDM4E B2RXH2 3/20 0.50
SERPINE1 P05121 1/20 0.47
KEAP1 Q14145 1/20 0.46
NFE2L2 Q16236 1/20 0.46
DAO P14920 1/20 0.46
TDP1 Q9NUW8 2/20 0.46
FEN1 P39748 1/20 0.44
ALDH1A1 P00352 2/20 0.44
CDC25A P30304 1/20 0.44
CDC25C P30307 1/20 0.44
NPC1 O15118 1/20 0.44
USP2 O75604 1/20 0.44
MAPT P10636 1/20 0.44
RAB9A P51151 1/20 0.44
KMT2A Q03164 1/20 0.44
PGR P06401 2/20 0.43
PADI4 Q9UM07 1/20 0.43
GLA P06280 1/20 0.43
GAA P10253 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13708850 0.86 GSK3B (0.54) GSK3BKDM4ESERPINE1KEAP1NFE2L2
SCHEMBL7813180 0.82 KDM4E (0.44) GSK3BKDM4EKEAP1NFE2L2DAO
SCHEMBL23510959 0.82 GRIN2D (0.58) GSK3BKDM4EALDH1A1MAPTKMT2A
SCHEMBL6046700 0.82 SERPINE1 (0.47) GSK3BKDM4ESERPINE1ALDH1A1NPC1
SCHEMBL1060499 0.81 KDM5A (0.59) GSK3BKDM4ESERPINE1ALDH1A1GAA
SCHEMBL7123791 0.80 KEAP1 (0.54) GSK3BKDM4EKEAP1NFE2L2DAO
SCHEMBL19952854 0.79 PADI4 (0.64) KMT2APADI4
SCHEMBL29612191 0.79 PADI4 (0.64) KMT2APADI4
SCHEMBL2284247 0.78 KDM4E (0.69) KDM4EDAOTDP1ALDH1A1NPC1
SCHEMBL21809222 0.76 KEAP1 (0.50) KDM4EKEAP1NFE2L2FEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050245563-A1 Chk-1 inhibitors MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-11-03 US disclosed
WO-2005028474-A2 PYRAZOLOQUINOLINE DERIVATIVES AS CHK-1 INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245563-A1 Chk-1 inhibitors CHKA, CHKB, CHEK1 GSK3B 824/4885KDM4E 1251/4885SERPINE1 1022/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.